Expert review of medical devices · 2025
Technology, pharmacology, and clinical outcomes of sirolimus coated balloons for peripheral arterial interventions.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khonkarn Ruttiros, Ramadani Pranvera, Qi Sheng, Ali Tariq, Krokidis Miltiadis
Аннотация
INTRODUCTION: Peripheral arterial intervention is a rapidly evolving field with a significant impact on an aging population.
AREAS COVERED: Treatment concepts evolve rapidly, with new therapies providing sustainable and cost-effective solutions for complex patients.
EXPERT OPINION: Metal stenting has been replaced by the 'leave-nothing-behind' approach, and plain balloon angioplasty devices have been replaced by drug-coated balloons (DCBs). While paclitaxel was initially used, sirolimus has more recently shown promising outcomes. This review article provides an overview of the technology and pharmacology behind sirolimus-coated balloons (SRL-DCB) and presents existing clinical evidence of their use.
AREAS COVERED: Treatment concepts evolve rapidly, with new therapies providing sustainable and cost-effective solutions for complex patients.
EXPERT OPINION: Metal stenting has been replaced by the 'leave-nothing-behind' approach, and plain balloon angioplasty devices have been replaced by drug-coated balloons (DCBs). While paclitaxel was initially used, sirolimus has more recently shown promising outcomes. This review article provides an overview of the technology and pharmacology behind sirolimus-coated balloons (SRL-DCB) and presents existing clinical evidence of their use.